Abstract:
Modern data about possibilities and perspectives of tumor necrosis factor blocking agents and leflunomide used for the disease-modifying treatment in patients with rheumatoid arthritis (RA) is presented. It has been revealed that the immunosuppressive drug leflunomide is effective in the treatment of RA and exerts therapeutic effects similar to those of the disease-modifying antirheumatic drugs (DMARD) therapy. Clinical trials have shown that parenteral administration of TNF neutralizing agents is remarkably effective at controlling signs and symptoms of RA in patients who have failed DMARD therapy, as well as in naïve patients.
